JERRY SALAMA has been a Principal of The Janus Property Company since 1998. The Janus Property Company is a recognized leader in the transformation of New York City's obsolete buildings and underutilized land areas into dynamic structures and vibrant neighborhoods.

Prior to Janus, Mr. Salama was Deputy Commissioner of the New York City Department of Housing Preservation and Development, Acting General Manager of the New York City Housing Authority and Counsel to the Deputy Mayor of New York for Finance and Economic Development. Earlier in his career, Mr. Salama was a real estate attorney with the law firm of Paul, Weiss, Rifkind, Wharton & Garrison.

Mr. Salama received a J.D. from Harvard Law School, a Master in Public Policy from Harvard's Kennedy School of Government and a Bachelor of Arts in Public Policy from the University of Pennsylvania. For the last 19 years, he has taught a course at the New York University School of Law entitled "Land Use, Housing and Community Development in New York City.

Dr. Hart has been involved with biomedical planning and development for nearly thirty (30) years. The bulk of this experience has

been with biotechnology development within an urban context. Dr. Hart was Master Developer of the 75-acre CrossTown

Industrial Park (CTIP) in Boston’s inner-city Roxbury neighborhood with the Community Development Corporation of Boston, Inc.

Dr. Hart was developer/project manager for the biotechnology facility that opened within this inner-city industrial park in 1989.

The biotech facility Dr. Hart developed with Boston University School of Medicine as anchor tenant that opened in 1989 included

labs and offices for university researchers and commercial firms, a biotech business incubator, and teaching labs for middle school

and high school students and teachers. This CityLab program provides a pipeline for the biotech industry and includes a mobile lab.

This biotech facility has evolved into BioSquare, the city of Boston’s premiere biotech business park. BioSquare includes over one

million square feet of labs and offices for university and commercial research and development, a tech transfer office, and one of

the four National Emerging Infectious Disease Laboratories in the United States.

Dr. Hart was a member of the LA Biosciences Coalition that was commissioned by LA County to create a plan to expand the

biosciences industry cluster in the region. This plan was approved by the LA County board of supervisors in 2016 and is now being

implemented by a newly created public agency BioSciencesLA (BioLA). This plan identifies up to nine potential biotech hubs in LA

County. Dr. Hart developed a Hub Readiness Index (HRI) to measure how feasible is it for a hub to become viable and what steps

are necessary to achieve success. This biotech hub development strategy is predicated upon Dr. Hart’s work in inner city Boston

which LA County hopes to duplicate. A similar strategy is the focus of the BioMed Development Group, LLC with the proposed

Murrietta BioMed Research Park.

Nancy J Kelley is a senior executive and lawyer with exceptional leadership ability and management skills. She has over twenty years of executive management and board experience in starting, growing, and restructuring organizations, raising capital, recruiting diverse management teams, creating and implementing strategic plans, developing real estate, developing internet based information platforms, data warehouses and marketing/branding. She has a particularly deep understanding of the healthcare, life science and research fields and has in-depth knowledge of the related legal, business, government, non-profit and academic sectors.

Nishta has extensive and specialized expertise in research, biotech, startups, entrepreneurship and academic partnerships with the goal of translating technologies to commercially viable therapies and products. Most recently, she served as Senior Director of Scientific Operations at Kadmon, a biotech startup based in New York City that focuses on discovery, development, and commercialization of small molecules and biologics. A molecular biologist by training, Nishta has scientific experience both in academia and industry.

Peter Schubert, FAIA is a Design Partner at Ennead Architects. Peter has spent over thirty-years designing award-winning office, commercial life science, vertical laboratories, R&D and innovation centers, academic science, mixed-use residential, hospital and hotel projects in the US and around the world. Fusing a passion for urbanism with iconic architecture that integrates local culture, history and context, he creates purposeful buildings and civic spaces. His work includes: Center East: The New York Blood Center, on the Upper East Side; The Cove Jersey City, a 3,000,000 SF commercial science-led mixed-use development; DIVCO West’s Parcel U project at Cambridge Crossing in MA; and the Alexandria Center for Life Science at East River Science Plaza, the first ground-up commercial lab project in New York City. Ennead has close to 5,000,000 sf of ground-up commercial lab projects across the Northeast. The firm is responsible for projects in the New York area as diverse as The Standard Hotel Highline, the new Koch Research Center at MSK and The Rose Planetarium.

Eugene R. Diaz is the founder and principal partner at Prism Capital Partners. Prism, began in 2002 with

a mission of strategically investing and developing solely in the Tri-State area, across a broad spectrum

of asset classes and transaction sizes. Today, the firm employs more than forty (40) professionals

providing construction, development, investment, and property management services to its many

institutional partners and investors. Through his stewardship, the firm remains one of the state’s most

active and respected redevelopers focusing on adaptive re-use and repurposing of excess corporate

facilities and turn of the century industrial buildings. The firm actively develops from the ground up for

multi-family, office, industrial and retail investments as well, and purchases both stabilized and un-

stabilized income producing assets. The firm has exhibited a strong investment discipline and a

corresponding track record that attracts joint venture equity capital from some of the most venerable

global investment management firms. Prism is leaving an indelible mark on the New Jersey landscape

with such notable redevelopments and adaptive reuses project like Parkway Lofts in Bloomfield, NJ, the

361 unit apartment conversion of the former 100 year old GE BoilerWorks Building on the Garden State

Parkway, as well as the 333 unit apartment conversion of the 100 year old historically designated Thomas

A Edison Battery and Invention Center in West Orange, NJ and the redevelopment of the 116 acre former

Roche Pharmaceutical headquarters known as ON 3, which houses the prestigious Hackensack-Meridian

Seton Hall College of Medicine. Previously, Diaz worked for Cushman & Wakefield and held several

leadership positions at Gale & Wentworth, including chief investment officer responsible for directing and

overseeing all aspects of the company's investment activities. During his tenure he grew the firm's owned

investment portfolio from 500,000 square feet to more than 12 million square feet in eight states.

Throughout his career, Diaz has been responsible for the acquisition and capitalization of more than 20

million square feet of commercial real estate with total transaction value in excess of $2.5 billion.. He is

frequently quoted in many industry publications as well as topical pieces in the New York Times and Wall

Street Journal. He earned a master's degree in Real Estate Investment & Development from New York

University, where he has frequented as a guest lecturer and stand-in professor. Diaz received

undergraduate degrees in Economics and Political Science from Northwestern University. Early in his

career Diaz was honored by Commercial Property News as one of their "Stars to Watch." and is regularly

ranked by NJBIZ as one of New Jersey’s most influential real estate people ranking him 3rd out of the 75

most influential leaders. He is a past member of the Board of Trustees of Englewood Hospital and an

Honorary Foundation Board Member of the Bergen Performing

John Pennett is the Partner-in-Charge of the Life Sciences

Group and Technology Group. He has 30 years of public

accounting experience, with a strong emphasis on public and

private life science and technology companies. John is a

frequent writer and speaker on topics related to issues impacting

businesses in the life sciences and technology space. He is the

publisher of Catalyst, a magazine focused solely on issues

related to life sciences and pharmaceutical companies. John

supports entrepreneurial organizations around the country with

content and program development, and serves as a mentor to

several early-stage companies.

John has led the accounting, auditing and strategic advisory

work for more than a hundred IPOs, private financing and

mergers and acquisitions with an aggregate valuation in excess

of $2 billion. In addition, he has served as the interim lead of the

firm’s Risk Advisory Practice, leading internal audit, contract

compliance and Sarbanes-Oxley implementation and testing.

He is deeply involved in the firm’s Outsourced Accounting

Services practice and the International Services Group. John

previously worked as an Audit Partner for an international

accounting and consulting firm.